phrykt

Attovia Therapeutics, Inc. (ATTO): who owns it and who trades it

As of Nov 16, 2026, ATTO insiders reported 22 open-market sales worth $2.2M and 7 purchases worth $42.1M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Colin Walsh (Director), with $2.2M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Attovia Therapeutics

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, ATTO insiders reported $42.1M of open-market purchases and $2.2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$42.1M
7 trades, 5 people
Sales, 12 months
$2.2M
22 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 6, 2026
Filed Aug 28, 2026

Purchases and sales by month

$42.1M$42.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 6, 2026Colin WalshDirectorPurchase500,000$17.00$8.5MForm 4
Aug 6, 2026venBio Global Strategic Fund IV, L.P.10% ownerPurchase382,352$17.00$6.5MForm 4
Aug 6, 2026Jeremy Green +210% ownerPurchase200,000$17.00$3.4MForm 4
Aug 6, 2026Jeremy Green +210% ownerPurchase400,000$17.00$6.8MForm 4
Aug 6, 2026Sanofi10% ownerPurchase300,000$17.00$5.1MForm 4
Aug 6, 2026Fhmls Xi, L.P. +210% ownerPurchase588,235$17.00$10MForm 4
Aug 5, 2026Colin WalshDirectorSale200$22.10$4.4KForm 4
Aug 5, 2026Colin WalshDirectorPurchase85,000$21.00$1.8MForm 4
Aug 5, 2026Colin WalshDirectorSale988$22.03$21.8KForm 4
Aug 5, 2026Colin WalshDirectorSale447$21.87$9.8KForm 4
Aug 5, 2026Colin WalshDirectorSale1,332$22.03$29.3KForm 4
Aug 5, 2026Colin WalshDirectorSale200$22.05$4.4KForm 4
Aug 5, 2026Colin WalshDirectorSale1,556$22.06$34.3KForm 4
Aug 5, 2026Colin WalshDirectorSale3,402$22.02$74.9KForm 4
Aug 5, 2026Colin WalshDirectorSale480$21.55$10.3KForm 4
Aug 5, 2026Colin WalshDirectorSale100$22.11$2.2KForm 4
Aug 5, 2026Colin WalshDirectorSale753$21.97$16.5KForm 4
Aug 5, 2026Colin WalshDirectorSale672$22.02$14.8KForm 4
Aug 5, 2026Colin WalshDirectorSale6,970$22.03$154KForm 4
Aug 5, 2026Colin WalshDirectorSale400$22.02$8.8KForm 4
Aug 5, 2026Colin WalshDirectorSale1,180$21.84$25.8KForm 4
Aug 5, 2026Colin WalshDirectorSale1,040$22.05$22.9KForm 4
Aug 5, 2026Colin WalshDirectorSale300$20.84$6.3KForm 4
Aug 5, 2026Colin WalshDirectorSale443$21.78$9.6KForm 4
Aug 5, 2026Colin WalshDirectorSale700$22.07$15.4KForm 4
Aug 5, 2026Colin WalshDirectorSale1,163$22.19$25.8KForm 4
Aug 5, 2026Colin WalshDirectorSale100$21.99$2.2KForm 4
Aug 5, 2026Colin WalshDirectorSale6,763$21.61$146KForm 4
Aug 5, 2026Colin WalshDirectorSale76,418$21.04$1.6MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Colin WalshDirector$10.3M$2.2MAug 6, 2026
Jeremy Green10% owner$10.2M–Aug 6, 2026
Fhmls Xi, L.P.10% owner$10M–Aug 6, 2026
venBio Global Strategic Fund IV, L.P.10% owner$6.5M–Aug 6, 2026
Sanofi10% owner$5.1M–Aug 6, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ATTO short interest

Low short interest. 3.5% of ATTO shares are sold short: about 1 share in 29. Over the last 6 reports the number of shares short went up 210%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.59M ATTO shares were sold short, 3.5% of the shares outstanding, up 9.3% from the report before. At the average daily volume of 352,555 shares, buying them all back would take about 4.5 trading days (days to cover).

Shares short, % of all shares

3.48%Aug 31Oct 303.94%

Days to cover

4.5Aug 14Oct 305.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.59M3.48%+9%352,5554.5
Oct 15, 20261.45M3.18%-12%416,5273.5
Sep 30, 20261.65M3.61%+98%553,8413.0
Sep 15, 2026831,0901.82%+28%207,2024.0
Aug 31, 2026648,5411.42%+27%212,0753.1
Aug 14, 2026511,865––732,9251.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Attovia Therapeutics company events

Attovia Therapeutics filed 3 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementThe Company recently announced positive topline 12-week results from its Phase 1b study of ATTO-1310, a next-generation anti-IL-31 ATTOBODY-based precision itch therapy, in patients with chronic pruritus and high-itch atopic dermatitis. Filing
  2. Sep 2, 2026ResultsReleased financial results. Filing
  3. Aug 6, 2026RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Famous investors that hold ATTO

3 of the 50 well-known investors we track reported holding ATTO in their latest 13F filing. The largest position is Israel Englander's, worth $8.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026476,261$8.2M0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026466,773$8M0.0%New
Steve Cohen · Point72 Asset ManagementQ3 2026180,664$3.1M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ATTO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026venBio Global Strategic Fund IV, L.P.13G9.2%
Nov 16, 2026venBio Global Strategic Fund IV, L.P.13G9.2%
Nov 13, 2026Alamar HoldCo, LLC13G7.1%
Nov 13, 2026GOLDMAN SACHS GROUP INC13G6.7%
Nov 13, 2026Alamar HoldCo, LLC13G7.1%
Nov 13, 2026GOLDMAN SACHS GROUP INC13G6.7%

Questions about Attovia Therapeutics, Inc. (ATTO) stock

Are ATTO insiders buying or selling?

In the last 12 months, ATTO insiders reported 7 open-market purchases worth $42.1M and 22 sales worth $2.2M. The latest trade was on Aug 6, 2026. See every trade.

What is the short interest in ATTO?

As of Oct 30, 2026, 1.59M ATTO shares were sold short, 3.5% of the shares outstanding, up 9.3% from the report before. At the average daily volume of 352,555 shares, buying them all back would take about 4.5 trading days (days to cover). See the history.

Which famous investors hold ATTO?

3 of the 50 well-known investors we track reported ATTO in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $8.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.